... Leading Expert Discusses Study During Late-Breaking Presentations at...CHICAGO April 1 2008 /- Final six-month follow-uppati...The findings from the SEISMIC(1) Trial a 40-patient randomizedmult... The results from the SEISMIC Trial are encouraging said Prof.Patri...

The findings from the SEISMIC(1) Trial, a 40-patient, randomized,
multicenter, controlled, Phase II-a study conducted in Europe, evaluated
MyoCell myoblast clinical cell therapy delivered via the MyoCath(R),
endoventricular needle-injection catheter in patients previously fitted
with implanted cardiac defibrillators(ICDs), receiving standard medical
therapy and who are experiencing congestive heart failure. On admission to
the trial, patients were randomized on a two-to-one ratio into the
treatment versus control groups with 26 patients receiving MyoCell therapy
and 14 patients in the control group. All patients were experiencing
congestive heart failure and were previously fitted with ICDs and receiving
standard medical therapy. Both the MyoCell biologic therapy and the MyoCath
needle-injection catheter, developed by Bioheart, Inc., are currently being
studied as investigational products.

"The results from the SEISMIC Trial are encouraging," said Prof.
Patrick W. Serruys, MD, PhD, Principal Investigator and Chief, Department
of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center -
Rotterdam, the Netherlands. "While the study was specifically designed to
show safety, the findings also suggest positive trends in clinical benefits
when evaluating the treated group versus the control group at six months."

Patients in both groups were evaluated at three- and six-month
intervals using a variety of tests, including digital imaging and standard
quality of life measurement such as the six-minute walking test, New York
Heart Association (NYHA) heart failure classification and Minnesota Living
with Heart (MLHF) questionnaire. Final six-month results observed in the
SEISMIC Trial include:

Prof. Serruys also noted that reports of arrhythmia among the patients
evaluated in SEISMIC, both in terms of total number of episodes as well as
timing of episodes, were no different between the treatment and control
arms in the study. This suggests that MyoCell is not associated with a
higher prevalence of arrhythmias; rather, that arrhythmias are an expected
occurrence for this subset of heart failure patients.

"These data support the need for a randomized, double-blind, placebo-
controlled study involving the MyoCell technology," said Prof. Serruys. "We
look forward to applying our learning from this trial to the larger, more
comprehensive MARVEL(2) Trial currently underway in the U.S. and Europe."
The MARVEL Trial, a randomized, double-blind, placebo-controlled,
multi-center Phase II/III Trial involving 330 patients in North America and
Europe, is the largest trial of its kind to date. Enrollment in the MARVEL
Trial began in October 2007, targeting patients who fall into Class II or
III heart failure. The MARVEL Trial will further study the safety and
efficacy of the minimally invasive MyoCell autologous stem-cell therapy in
the treatment of congestive heart failure delivered via a MyoStar(TM)
injection catheter(3), in combination with the NOGA(R) XP Cardiac
Navigation System. The Principal Investigator for the MARVEL Trial is
Warren Sherman, MD, Director, Cardiac Cell-based Endovascular Therapies,
Columbia University Medical Center, New York.

ABOUT MYOCELL CLINICAL CELL THERAPY

MyoCell clinical cell therapy, developed by Bioheart, Inc., is
currently being studied as an investigational product in Europe and the
U.S. MyoCell clinical cell therapy is intended to be used to improve
cardiac function months or even years after a patient has suffered severe
heart damage due to a heart attack. The procedure involves a physician
removing a small amount of muscle obtained from the patient's thigh. From
this muscle specimen, autologous myoblasts (muscle stem cells) are then
isolated, grown using Bioheart's proprietary cell-culturing process, and
injected directly into the scar tissue of the patient's heart. The myoblast
cells are delivered via an endoventricular needle-injection catheter during
a minimally invasive procedure performed by an interventional cardiologist
or vascular surgeon. The myoblast-based muscle formation in the newly
populated regions of scar tissue are intended to improve cardiac function
by helping the heart muscle beat more efficiently.

ABOUT HEART DISEASE

Approximately nine million European patients and 5.2 million
Americans(4) suffer from congestive heart failure, a progressively
degenerative condition in which the heart is unable to adequately pump
blood throughout the body resulting in fluid accumulation in the lungs,
kidneys, and other body tissues. Patients suffering from this disease
fatigue easily, and become increasingly less capable of normal activity as
they progress through the various stages of the disease. Current standard
of care typically involves drug therapy and/or the implantation of a
pacemaker and/or defibrillator device to regulate heart function.

ABOUT BIOHEART, INC.

Bioheart, Inc. is a biotechnology company focused on the discovery,
development and, subject to regulatory approval, commercialization of
autologous cell therapies for the treatment of chronic and acute heart
damage. Its lead product candidate, MyoCell, is an innovative clinical cell
therapy designed to populate regions of scar tissue within a patient's
heart with autologous muscle cells, or cells from the patient's body, for
the purpose of improving cardiac function in chronic heart failure
patients. The company's pipeline includes multiple product candidates for
the treatment of heart damage, including Bioheart Acute Cell Therapy, an
autologous, adipose cell treatment for acute heart damage, and MyoCell
SDF-1, a therapy utilizing autologous cells genetically modified to express
additional growth factors.

(Date:12/8/2016)... 8, 2016 Boehringer Ingelheim announced today that it ... (CEI). This is the ninth time that the company ... a Best Place to Work for LGBT Equality. Administered ... a national benchmarking report on corporate policies and practices ... transgender (LGBT) employees. "We are committed ...

(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...

(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital health ... led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and ... to serve more consumers who are managing chronic conditions or simply want ...

(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...

(Date:12/8/2016)... ... 08, 2016 , ... Bill Mull Agencies, a Wichita-based firm ... around central Kansas, is joining the Youth Horizons organization for a charity event ... in Wichita, Youth Horizons works to empower area children from unstable, troubled, or ...

(Date:12/7/2016)... ... , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more than ... multi-function, sealed, LED luminaire that meets the needs of everyone in the patient room ... , A 2’ x 4’ model features four modes: reading, ambient, standard and ...